舒芬太尼联合罗派卡因在无痛分娩中的临床应用
|
摘要
目的探讨舒芬太尼联合罗派卡因在无痛分娩中的临床应用价值。方法本研究回顾分析本院产科2017年1月至2017年12月之间收治150例无痛分娩产妇的临床资料,随机分为联合用药组、罗派卡因组和对照组,对照组不应用任何类型的麻醉药物,罗派卡因组应用单一罗派卡因,联合用药组在无痛分娩中应用舒芬太尼和罗派卡因,比较3组分娩结果和新生儿情况。结果 3组观察对象第一产程和第二产程时间,以及新生儿Apgar评分结果比较,差异均无明显的统计学意义。联合用药组第一产程活跃期小于2.5 h占比、剖宫产率和产后出血发生率均明显低于罗派卡因组和对照组,差异有统计学意义(P<0.05),而3组产妇缩宫素使用率比较则无明显的统计学意义。3组产妇分娩后运动阻滞情况比较差异无统计学意义,而其疼痛程度则明显轻于罗派卡因组和对照组,3组差异比较存在明显的统计学意义(P<0.05)。结论在产妇无痛分娩过程中应用舒芬太尼联合罗派卡因麻醉,有助于产妇的顺利安全分娩,缩短产程时间,保证产妇和新生儿健康。
Objective To investigate the clinical value of sufentanil combined with ropivacaine in painless labor. Methods This study reviewed the clinical data of 150 patients undergoing painless delivery during obstetrics in our department of obstetrics from January 2017 to December 2017. The clinical data were randomly divided into the combination group, the capecine group and the control group. The control group was not applied. For any type of anesthetic drug, ropivacaine group was treated with single ropivacaine, and the combination group was given sufentanil and ropivacaine in painless labor to compare the results of three components and neonatal conditions. Results There was no significant difference between the three groups in the first stage of labor and the second stage of labor, and the results of neonatal Apgar scores. The proportion of active period of less than 2.5 hours in the first stage of labor, the rate of cesarean section and postpartum hemorrhage in the combination group were significantly lower than those in the Ropcaine group and the control group(P<0.05), while the use of oxytocin in the three groups was significantly lower. There was no statistically significant difference. There was no statistically significant difference in maternal motion retardation after delivery,but the degree of pain in the three groups was significantly lower than those in the Ropcaine group and the control group. The difference between the three groups was statistically significant(P<0.05). Conclusion Sufentanil combined with ropivacaine anesthesia in the painless parturition process of maternal women is helpful for the smooth and safe delivery of mothers, shortening the labor time and ensuring maternal and newborn health.
Objective To investigate the clinical value of sufentanil combined with ropivacaine in painless labor. Methods This study reviewed the clinical data of 150 patients undergoing painless delivery during obstetrics in our department of obstetrics from January 2017 to December 2017. The clinical data were randomly divided into the combination group, the capecine group and the control group. The control group was not applied. For any type of anesthetic drug, ropivacaine group was treated with single ropivacaine, and the combination group was given sufentanil and ropivacaine in painless labor to compare the results of three components and neonatal conditions. Results There was no significant difference between the three groups in the first stage of labor and the second stage of labor, and the results of neonatal Apgar scores. The proportion of active period of less than 2.5 hours in the first stage of labor, the rate of cesarean section and postpartum hemorrhage in the combination group were significantly lower than those in the Ropcaine group and the control group(P<0.05), while the use of oxytocin in the three groups was significantly lower. There was no statistically significant difference. There was no statistically significant difference in maternal motion retardation after delivery,but the degree of pain in the three groups was significantly lower than those in the Ropcaine group and the control group. The difference between the three groups was statistically significant(P<0.05). Conclusion Sufentanil combined with ropivacaine anesthesia in the painless parturition process of maternal women is helpful for the smooth and safe delivery of mothers, shortening the labor time and ensuring maternal and newborn health.
引文
[1]李新鹏,王世民.罗派卡因复合舒芬太尼蛛网膜下腔阻滞麻醉用于肥胖剖宫产患者的临床观察[J].吉林医学,2017,38(6):1110-1111.
[2]王卫华,王尚柯,许莉芳,等.罗哌卡因复合舒芬太尼蛛网膜下腔阻滞麻醉在剖宫产术中应用的效果[J].中国医师杂志,2010,12(11):1576-1577.
[3]邱郁群,王玉玲,陈艳,等.盐酸罗派卡因复合舒芬太尼硬膜外术后镇痛对产妇泌乳的影响[J].实用临床医学,2013,14(3):41-42.
[4]王莹.罗呱卡因复合舒芬太尼硬膜外自控分娩镇痛的临床观察[J].中国实用医药,2012,7(27):179-180.
[5]贾兰芹.罗哌卡因复合舒芬太尼硬膜外分娩镇痛的临床观察[J].中国社区医师(医学专业),2012,14(13):148-149.
[6]McLennan MT,Melick CF,Alten B,et al.Patients'knowledge of potential pelvic floor changes associated with pregnancy and delivery[J].International Urogynecology Journal PelvicFloor Dysfunction,2006,17(1):22-26.
[7]孙慧.盐酸罗哌卡因联合舒芬太尼硬膜外麻醉无痛分娩的临床疗效[J].当代医学,2018,24(22):159-160.
[8]Diez-tza I,Arrue M,Ibaiez L,et a1.Postpartum impairment ofpelvic floor muscle function:factom involved and association withprolapse[J].Int Urogynecol,2011,22(12):1505-1511.
[9]张健.舒芬太尼复合罗派卡因在剖宫产术后硬膜外镇痛的应用效果分析[J].中国保健营养,2014,1(5):2821-2822.
[10]马彦利,姜丽华.小剂量氯胺酮联合舒芬太尼用于剖宫产术后镇痛的临床研究[J].中国实用医刊,2017,44(14):99-100.
[11]曾夷,李艳梅,罗家芳,等.无痛分娩与传统阴道分娩对初产产妇母婴结局、母乳喂养情况的影响观察[J].当代医学,2018,24(21):36-37.
[2]王卫华,王尚柯,许莉芳,等.罗哌卡因复合舒芬太尼蛛网膜下腔阻滞麻醉在剖宫产术中应用的效果[J].中国医师杂志,2010,12(11):1576-1577.
[3]邱郁群,王玉玲,陈艳,等.盐酸罗派卡因复合舒芬太尼硬膜外术后镇痛对产妇泌乳的影响[J].实用临床医学,2013,14(3):41-42.
[4]王莹.罗呱卡因复合舒芬太尼硬膜外自控分娩镇痛的临床观察[J].中国实用医药,2012,7(27):179-180.
[5]贾兰芹.罗哌卡因复合舒芬太尼硬膜外分娩镇痛的临床观察[J].中国社区医师(医学专业),2012,14(13):148-149.
[6]McLennan MT,Melick CF,Alten B,et al.Patients'knowledge of potential pelvic floor changes associated with pregnancy and delivery[J].International Urogynecology Journal PelvicFloor Dysfunction,2006,17(1):22-26.
[7]孙慧.盐酸罗哌卡因联合舒芬太尼硬膜外麻醉无痛分娩的临床疗效[J].当代医学,2018,24(22):159-160.
[8]Diez-tza I,Arrue M,Ibaiez L,et a1.Postpartum impairment ofpelvic floor muscle function:factom involved and association withprolapse[J].Int Urogynecol,2011,22(12):1505-1511.
[9]张健.舒芬太尼复合罗派卡因在剖宫产术后硬膜外镇痛的应用效果分析[J].中国保健营养,2014,1(5):2821-2822.
[10]马彦利,姜丽华.小剂量氯胺酮联合舒芬太尼用于剖宫产术后镇痛的临床研究[J].中国实用医刊,2017,44(14):99-100.
[11]曾夷,李艳梅,罗家芳,等.无痛分娩与传统阴道分娩对初产产妇母婴结局、母乳喂养情况的影响观察[J].当代医学,2018,24(21):36-37.